We also found four druggable genes: FZD7, LY96, PTGIS, and CFH. FZD7 is a direct target of vantictumab, a neutralizing antibody currently being developed as an anticancer agent, particularly for triple-negative breast cancer (72, 73). Here, FZD7 is linked to triple-negative breast carcinoma.